OBJECTIVE: Thimerosal is an important preservative in vaccines and ophthalmologic preparations. The substance is known to be a type IV sensitizing agent. High sensitization rates were observed in contact-allergic patients and in health care workers who had been exposed to thimerosal-preserved vaccines. There is evidence for the involvement of the glutathione system in the metabolism of thimerosal or its decomposition products (organomercury alkyl compounds). Thus detoxification by polymorphically expressed glutathione S-transferases such as GSTT1 and GSTM1 might have a protective effect against sensitization by these substances. METHODS: To address this question, a case control study was conducted, including 91 Central European individuals with a positive patch-test reaction to thimerosal. This population was compared with 169 healthy controls and additionally with 114 individuals affected by an allergy against para-substituted aryl compounds. The latter population was included in order to test whether possible associations were due to substance-specific effects, or were a general feature connected with type IV immunological diseases. Homozygous deletions of GSTT1 and GSTM1 were determined by polymerase chain reaction. RESULTS: Glutathione S-transferase M1 deficiency was significantly more frequent among patients sensitized to thimerosal (65.9%, P = 0.013) compared with the healthy control group (49.1%) and the "para-compound" group (48%, P = 0.034). Glutathione S-transferase T1 deficiency in the thimerosal/mercury group (19.8%) was barely elevated versus healthy controls (16.0%) and the "para-compound" group (14.0%). The combined deletion (GSTT1-/GSTM1-) was markedly more frequent among thimerosal-sensitized patients than in healthy controls (17.6% vs. 6.5%, P = 0.0093) and in the "para-compound" group (17.6% vs. 6.1%, P =0.014), revealing a synergistic effect of these enzyme deficiencies (healthy controls vs. thimerosal GSTM1 negative individuals, OR = 2.0 [CI = 1.2-3.4], GSTT1-, OR = 1.2 [CI = 0.70-2.1], GSTM1/T1-, OR = 3.1 [CI = 1.4-6.5]). CONCLUSIONS: Since the glutathione-dependent system was repeatedly shown to be involved in the metabolism of thimerosal decomposition products, the observed association may be of functional relevance.
OBJECTIVE:Thimerosal is an important preservative in vaccines and ophthalmologic preparations. The substance is known to be a type IV sensitizing agent. High sensitization rates were observed in contact-allergicpatients and in health care workers who had been exposed to thimerosal-preserved vaccines. There is evidence for the involvement of the glutathione system in the metabolism of thimerosal or its decomposition products (organomercury alkyl compounds). Thus detoxification by polymorphically expressed glutathione S-transferases such as GSTT1 and GSTM1 might have a protective effect against sensitization by these substances. METHODS: To address this question, a case control study was conducted, including 91 Central European individuals with a positive patch-test reaction to thimerosal. This population was compared with 169 healthy controls and additionally with 114 individuals affected by an allergy against para-substituted aryl compounds. The latter population was included in order to test whether possible associations were due to substance-specific effects, or were a general feature connected with type IV immunological diseases. Homozygous deletions of GSTT1 and GSTM1 were determined by polymerase chain reaction. RESULTS:GlutathioneS-transferase M1 deficiency was significantly more frequent among patients sensitized to thimerosal (65.9%, P = 0.013) compared with the healthy control group (49.1%) and the "para-compound" group (48%, P = 0.034). Glutathione S-transferase T1 deficiency in the thimerosal/mercury group (19.8%) was barely elevated versus healthy controls (16.0%) and the "para-compound" group (14.0%). The combined deletion (GSTT1-/GSTM1-) was markedly more frequent among thimerosal-sensitized patients than in healthy controls (17.6% vs. 6.5%, P = 0.0093) and in the "para-compound" group (17.6% vs. 6.1%, P =0.014), revealing a synergistic effect of these enzyme deficiencies (healthy controls vs. thimerosalGSTM1 negative individuals, OR = 2.0 [CI = 1.2-3.4], GSTT1-, OR = 1.2 [CI = 0.70-2.1], GSTM1/T1-, OR = 3.1 [CI = 1.4-6.5]). CONCLUSIONS: Since the glutathione-dependent system was repeatedly shown to be involved in the metabolism of thimerosal decomposition products, the observed association may be of functional relevance.
Authors: M Peiser; T Tralau; J Heidler; A M Api; J H E Arts; D A Basketter; J English; T L Diepgen; R C Fuhlbrigge; A A Gaspari; J D Johansen; A T Karlberg; I Kimber; J P Lepoittevin; M Liebsch; H I Maibach; S F Martin; H F Merk; T Platzek; T Rustemeyer; A Schnuch; R J Vandebriel; I R White; A Luch Journal: Cell Mol Life Sci Date: 2011-10-14 Impact factor: 9.261
Authors: Jennifer M Reinhart; Alison Motsinger-Reif; Allison Dickey; Steven Yale; Lauren A Trepanier Journal: PLoS One Date: 2016-06-07 Impact factor: 3.240
Authors: Andréia Ávila Soares de Oliveira; Marilesia Ferreira de Souza; André van Helvoort Lengert; Marcelo Tempesta de Oliveira; Rossana Batista de Oliveira Godoy Camargo; Gilberto Úbida Leite Braga; Ilce Mara de Syllos Cólus; Fernando Barbosa; Gustavo Rafael Mazzaron Barcelos Journal: Biomed Res Int Date: 2014-02-18 Impact factor: 3.411
Authors: Mohammad H Rahbar; Maureen Samms-Vaughan; Jianzhong Ma; Jan Bressler; Katherine A Loveland; Manouchehr Ardjomand-Hessabi; Aisha S Dickerson; Megan L Grove; Sydonnie Shakespeare-Pellington; Compton Beecher; Wayne McLaughlin; Eric Boerwinkle Journal: Int J Environ Res Public Health Date: 2014-08-06 Impact factor: 3.390
Authors: Francisco J Sánchez-Gómez; Beatriz Díez-Dacal; Elena García-Martín; José A G Agúndez; María A Pajares; Dolores Pérez-Sala Journal: Front Pharmacol Date: 2016-08-04 Impact factor: 5.810